OncLive® On Air

506 Epizód

1. S14 Ep30: FDA Approval Insights: Subcutaneous Pembrolizumab for Solid Tumors: With J. Thaddeus Beck, MD, FACP

   Közzétéve: 2025. 10. 16.
2. S14 Ep29: Passion and Innovation Formed the Foundation for a Leading Cancer Program: With Girindra Raval, MD; and Anand Jillella, MD

   Közzétéve: 2025. 10. 15.
3. S14 Ep28: Oncology Experts Preview Key Studies Ahead of the 2025 ESMO Congress

   Közzétéve: 2025. 10. 13.
4. S14 Ep27: FDA Approval Insights: Gemcitabine Intravesical System for NMIBC: With Joseph Jacob, MD, MCR

   Közzétéve: 2025. 10. 09.
5. S14 Ep26: FDA Approval Insights: Sunvozertinib in EGFR-Mutated Metastatic NSCLC: With Lyudmila Bazhenova, MD

   Közzétéve: 2025. 10. 08.
6. S14 Ep25: Sequencing, Efficacy, and Safety Data May Further Evolve the Role of Fruquintinib in CRC: With Kanwal P. S. Raghav, MBBS, MD

   Közzétéve: 2025. 10. 06.
7. S14 Ep24: FDA Approval Insights: Maintenance Lurbinectedin Plus Atezolizumab for ES-SCLC: With Anne Chiang, MD, PhD; and Stephen Liu, MD

   Közzétéve: 2025. 10. 02.
8. S14 Ep23: Early Biomarker Testing Optimizes Tepotinib Use in NSCLC With MET Exon 14 Skipping Mutations: With Stephen Liu, MD

   Közzétéve: 2025. 10. 01.
9. S14 Ep22: Expanding JAK Inhibitor Use Offers Increased Treatment Options for Cytopenic Myelofibrosis: With Andrew Kuykendall, MD

   Közzétéve: 2025. 09. 29.
10. S14 Ep21: Early CAR T-Cell Therapy Data Highlight Therapeutic Potential and Emerging Challenges in GI Cancers: With Kohei Shitara, MD

    Közzétéve: 2025. 09. 25.
11. S14 Ep20: The Evolving Role of Noncovalent BTK Inhibition Informs CLL Treatment Selection: With Asad Dean, MD

    Közzétéve: 2025. 09. 24.
12. S14 Ep19: Zidesamtinib Is Associated With CNS Activity and Low Rates of Neurologic AEs in Pretreated ROS1+ NSCLC: With Alexander Drilon, MD

    Közzétéve: 2025. 09. 18.
13. S14 Ep18: Patient Characteristics and Disease Factors Guide the Use of Dostarlimab in Recurrent Endometrial Cancer: With Dana M. Chase, MD

    Közzétéve: 2025. 09. 17.
14. S14 Ep17: Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

    Közzétéve: 2025. 09. 16.
15. S14 Ep16: Establishing the Rationale for ADC and ICI Combinations in TNBC

    Közzétéve: 2025. 09. 16.
16. S14 Ep15: Cohort Analysis Shows Importance of Early-Onset CRC Awareness and Investigation: With Evelyn Y. Wong, MD

    Közzétéve: 2025. 09. 15.
17. S14 Ep14: Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

    Közzétéve: 2025. 09. 15.
18. S14 Ep13: Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

    Közzétéve: 2025. 09. 15.
19. S14 Ep12: Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

    Közzétéve: 2025. 09. 12.
20. S14 Ep11: Breaking Down the Rationale for Targeting TROP2 in TNBC

    Közzétéve: 2025. 09. 12.